Lung Cancer Liquid Biopsy Market Size to Hit US$ 1,900.5 Million by 2032, Reports Persistence Market Research

The global lung cancer liquid biopsy market is poised to witness substantial growth, with the market size expected to reach US$ 1,900.5 million by 2032, up from US$ 824.7 million in 2025, growing at a robust CAGR of 12.7% from 2025 to 2032, as per a recent report by Persistence Market Research. This growth trajectory is largely driven by the increasing incidence of lung cancer globally, coupled with rising demand for non-invasive diagnostic techniques that promise early-stage detection, personalized treatment options, and minimized patient discomfort.

Compared to traditional tissue biopsies, liquid biopsies utilize blood-based biomarkers such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes to detect and monitor lung cancer. This non-invasive approach provides significant advantages, including faster diagnosis, reduced risk of complications, and the ability to monitor treatment response and recurrence, which has further fueled market demand.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35195

Key Industry Highlights

NGS-based Multi-Gene Parallel Analysis: In 2024, NGS-based technologies dominated the market due to their ability to conduct comprehensive genomic profiling, making them the preferred method for liquid biopsy tests. By analyzing multiple genes simultaneously, NGS facilitates a deeper understanding of genetic mutations and tumor evolution.

Emerging Technologies: Novel technologies such as Whole Genome Amplification (WGA) and Digital PCR are improving the sensitivity and precision of liquid biopsies, making it easier to detect even low-abundance mutations. These innovations are expected to expand the applications of liquid biopsy, especially for early cancer detection.

Regional Trends: North America continues to lead the lung cancer liquid biopsy market, owing to its high incidence of lung cancer and advanced healthcare infrastructure. The Asia Pacific region, however, is the fastest-growing market, with significant strides in adoption seen in China, Japan, and India.

Challenges: While liquid biopsy technologies are gaining momentum, the standardization of testing protocols and high costs of advanced diagnostic tools remain barriers to widespread adoption, particularly in low-resource settings.

Market Dynamics
Drivers

Advances in Liquid Biopsy Technologies and Biomarker Discovery: Continuous innovation in liquid biopsy technologies and the discovery of new biomarkers are significantly driving the market. Key biomarkers such as microRNAs, gene mutations, and proteins are being studied for their potential in early cancer detection, improving diagnostic accuracy, and helping track cancer progression and treatment response.

Increased Funding and Collaborations: Collaborations between hospitals, research centers, and biotech companies are accelerating the development of liquid biopsy tests. For example, BioMark Diagnostics' pivotal lung cancer screening study, initiated in January 2023, aims to combine metabolomics liquid biopsy tests with genetic biomarkers to enhance detection accuracy.

Restraints

Limited Sensitivity in Early-Stage Cancer Detection: A major challenge in the widespread adoption of liquid biopsies lies in their sensitivity, especially for early-stage cancers. Tumor-derived biomarkers like ctDNA and CTCs are often present in minute quantities during the early stages, making it difficult to detect the cancer reliably at that stage.

High Costs and Lack of Standardization: Liquid biopsy technologies, especially NGS and PCR-based methods, are expensive, which limits their accessibility, particularly in developing regions. The lack of standardized testing protocols further complicates the integration of liquid biopsies into routine clinical practice.

Opportunities

Rising Demand for Companion Diagnostics in Targeted Lung Cancer Treatments: The use of liquid biopsy as a companion diagnostic tool (CDx) for personalized treatments is a key growth driver. Liquid biopsies are used to identify genetic mutations in lung cancer patients that can be targeted by specific therapies like EGFR inhibitors and ALK inhibitors. As targeted therapies gain popularity, the demand for liquid biopsy as a CDx tool is expected to increase.

Precision Medicine: As healthcare continues to shift toward precision medicine, liquid biopsies are increasingly used to identify patients who are likely to benefit from personalized treatments, thus providing a significant growth opportunity in the lung cancer liquid biopsy market.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/lung-cancer-liquid-biopsy-market.asp

Category-wise Analysis

Product Insights

Consumables, including kits and reagents, accounted for a significant share (71.2%) of the market in 2024. These consumables are essential for collecting, processing, and analyzing patient samples, and their frequent usage in diagnostic tests ensures a steady revenue stream. As liquid biopsy technologies become more integrated into clinical practice, the demand for consumables is expected to rise proportionally.

Technology Insights

NGS-based multi-gene parallel analysis held the largest market share (75.2%) in 2024. This technology offers the ability to simultaneously analyze multiple genetic mutations, making it a preferred choice for molecular profiling in lung cancer diagnostics. With advancements in NGS technology, the ability to target specific mutations and personalize treatment plans is set to further strengthen its market dominance.

Regional Insights and Trends

North America

North America held the largest market share of 47.8% in 2024. The increasing prevalence of lung cancer in the region, coupled with the high adoption of innovative diagnostic technologies, has significantly contributed to the growth of the liquid biopsy market. The U.S. alone is expected to report around 226,650 new cases of lung cancer in 2025, with a majority of those being non-small cell lung cancer (NSCLC). Government investments and collaborations, such as Roche's partnership with Freenome, are expected to accelerate the development of advanced liquid biopsy technologies.

Europe

Europe accounted for 28.6% of the global market share in 2024. European countries, particularly Germany and the U.K., have made substantial investments in liquid biopsy research and development. The U.K.'s National Health Service (NHS) and Germany's strong regulatory framework are helping to integrate liquid biopsy technologies into clinical settings. Partnerships, such as Guardant Health's collaboration with The Royal Marsden, are further driving the adoption of liquid biopsy in Europe.

Asia Pacific

Asia Pacific is projected to grow at a CAGR of 15.6% during the forecast period. This growth is driven by the increasing burden of lung cancer in countries like China, India, and Japan. Local biotech companies are focusing on developing affordable liquid biopsy solutions tailored to the region's needs. Government initiatives, such as Johnson & Johnson's "India Detects to Defeat" campaign, are also playing a critical role in boosting awareness and early detection of lung cancer.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35195

Competitive Landscape

The lung cancer liquid biopsy market is highly competitive, with several key players focusing on technological advancements and strategic partnerships. The increasing demand for personalized medicine and non-invasive diagnostic solutions is driving competition in the space.

Key Players

Guardant Health, Inc.
Bio-Rad Laboratories, Inc.
QIAGEN
Thermo Fisher Scientific Inc.
Freenome Holdings, Inc.
Foundation Medicine, Inc.
Illumina, Inc.
SOPHiA GENETICS
Agilent Technologies, Inc.

These companies are heavily investing in research and development to launch advanced liquid biopsy solutions. For instance, Guardant Health has teamed up with Boehringer Ingelheim to seek regulatory approval for the Guardant360® CDx liquid biopsy as a companion diagnostic for targeted therapies like zongertinib in NSCLC.

Recent Developments

January 2025: Viz.ai partnered with Guardant Health to integrate artificial intelligence (AI) with liquid biopsy, enhancing early lung cancer detection through its Viz.ai One platform.

December 2024: Guardant Health and Boehringer Ingelheim sought regulatory approval for the Guardant360® CDx as a companion diagnostic for lung cancer therapies.

March 2024: Guardant Health collaborated with The Royal Marsden to expand the use of liquid biopsy in the U.K., aiming to improve lung cancer treatment and diagnosis.

Future Outlook

The lung cancer liquid biopsy market is expected to continue its growth trajectory due to ongoing technological advancements and the increasing shift toward personalized medicine. The development of more sensitive and accurate biomarker detection technologies, coupled with expanding clinical applications, will play a key role in shaping the future of the market. As liquid biopsy tests become more affordable and accessible, their adoption will likely become the standard of care for lung cancer diagnostics in the coming years.

Read More Related Reports:

Eeg Biosensors Market https://www.persistencemarketresearch.com/market-research/eeg-biosensors-market.asp
Nasal Antiseptics Market https://www.persistencemarketresearch.com/market-research/nasal-antiseptics-market.asp
Tcr Based Antibody Market https://www.persistencemarketresearch.com/market-research/tcr-based-antibody-market.asp
Urea Breath Test Systems Market https://www.persistencemarketresearch.com/market-research/urea-breath-test-systems-market.asp
Europe Urethral Bulking Systems Market https://www.persistencemarketresearch.com/market-research/europe-urethral-bulking-systems-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.